Ohio State Navbar

Sign In

RSS Feed Regenerative Medicine News


AlloCure Begins Phase 2 Clinical Trial in Acute Kidney Injury 

 

 

AlloCure Begins Phase 2 Clinical Trial in Acute Kidney Injury
September 4, 2012 - (AlloCure) - "AlloCure, Inc. today announced that it has initiated a phase 2 clinical trial of AC607, the company's mesenchymal stem cell therapy, as a potential treatment for acute kidney injury (AKI). The randomized, double-blind, placebo-controlled, multi-center trial, designated ACT-AKI (AC607 Trial in Acute Kidney Injury) (NCT01602328), will enroll 200 cardiac surgery subjects at leading tertiary care centers in the United States."  Read Full Article

 

 

Posted on 6-Sep-12 by Toto, Brent
Tags: Science and Industry News
 
Trackback Url  |  Link to this post | Bookmark this post with: